Comprehensive characterization of protein glycosylation is critical for understanding the structure and function of glycoproteins. However, due to the complexity and heterogeneity of glycoprotein conformations, current glycoprotein analyses focus mainly on either the deglycosylated glycosylation site (glycosite)-containing peptides or the released glycans. Here, we describe a chemoenzymatic method called solid phase extraction of N-linked glycans and glycosite-containing peptides (NGAG) for the comprehensive characterization of glycoproteins that is able to determine glycan heterogeneity for individual glycosites in addition to providing information about the total N-linked glycan, glycosite-containing peptide and glycoprotein content of complex samples. The NGAG method can also be applied to quantitatively detect glycoprotein alterations in total and site-specific glycan occupancies.
l e t t e r s
Comprehensive characterization of protein glycosylation is critical for understanding the structure and function of glycoproteins. However, due to the complexity and heterogeneity of glycoprotein conformations, current glycoprotein analyses focus mainly on either the deglycosylated glycosylation site (glycosite)-containing peptides or the released glycans. Here, we describe a chemoenzymatic method called solid phase extraction of N-linked glycans and glycosite-containing peptides (NGAG) for the comprehensive characterization of glycoproteins that is able to determine glycan heterogeneity for individual glycosites in addition to providing information about the total N-linked glycan, glycosite-containing peptide and glycoprotein content of complex samples. The NGAG method can also be applied to quantitatively detect glycoprotein alterations in total and site-specific glycan occupancies.
Protein glycosylation is one of the most common and important protein modifications 1, 2 . It plays fundamental roles in many biological processes and in the pathological progression of many diseases, and glycoproteins are a major class of current therapeutic targets and clinical biomarkers 3 . Protein glycosylation is also the most structurally complicated and diverse type of protein modification 1 . Each glycoprotein can contain multiple glycosites, and each glycosite can be modified by multiple different glycans 1 . Glycoprotein characterization often entails determining the fraction of protein that is glycosylated, where the glycosites are located, the occupancy of each glycosite and which glycan structures are associated with each glycosite [4] [5] [6] . The complexity of glycosylation heterogeneity poses great challenges for the identification of specific glycosylation patterns that are associated with different biological functions and diseases.
In the last decade, mass spectrometry (MS)-based glycoproteomics and glycomics have become emerging technologies for the largescale characterization of glycoproteins [4] [5] [6] [7] . These methods include (i) physical-chemical methods such as chromatography 8, 9 , peptide sequencing 10 and electrophoresis 11 ; (ii) methods using affinity-based reagents such as lectins and antibodies 5, 12, 13 ; and (iii) tagging glycan moieties using enzymes 14 , chemicals 4, 15 or metabolic labeling 16 .
Recent developments in MS-based technologies also enable intact glycopeptide analysis [17] [18] [19] [20] [21] [22] [23] [24] [25] . These techniques have provided valuable insights into the interdependence of glycoprotein structure and protein function. However, these technologies focus mainly on the analysis of either released glycans or deglycosylated peptides, or concentrate on glycopeptides, and lack the capability to simultaneously analyze all relevant parameters such as total glycans, glycoproteins and their glycosites, as well as site-specific glycosylation, especially in complex biological or clinical samples.
In this study, we developed a chemoenzymatic method termed solid phase extraction of NGAG for the comprehensive characterization of N-linked glycoproteins. The NGAG method includes seven steps ( Fig. 1a and Supplementary Fig. 1 ). (i) Protein samples were digested into peptides, followed by guanidination to block the ε-amino groups on the side chain of lysine residues 26 . (ii) Peptides were covalently conjugated to an aldehyde-functionalized solid support through their N termini (α-amino groups). (iii) Carboxyl groups of aspartic acid (D), glutamic acid (E), and peptide C termini were modified with aniline. At the same time sialic acids on the sialylated glycopeptides were also modified by aniline to facilitate mass spectrometric detection of sialylated glycans 15 . (iv) N-linked glycans were released from the solid support by PNGase F digestion, in parallel with conversion of asparagine residues at N-linked glycosites to aspartic acid residues by deamination. (v) Glycosite-containing peptides with aspartic residues at N-glycosites were specifically released from solid phase by Asp-N digestion. Asp-N specifically cleaves peptide bonds N-terminal to aspartic acid residues. However, because all original aspartic acid residues of the peptides were modified with esterification, only newly generated aspartic acid residues at the N-glycosites after N-glycan release were cleaved by Asp-N. (vi) The released N-glycans and glycosite-containing peptides were identified by MS. (vii) The intact N-glycopeptides were then reconstructed by assigning the oxonium ions-containing MS/MS spectra extracted from global proteomic or enriched glycopeptide data to the glycopeptide candidate database, which was comprised of all possible combinations of identified glycans and glycosite-containing peptides (Fig. 1b) .
First, we tested our method on bovine fetuin and determined glycan content, glycosites, total glycoproteins and site-specific glycosylation in Table 3) , of which 52 contained fucose, 38 contained sialic acid, 23 contained both fucose and sialic acid residues and 8 were of the oligo-mannose type (Fig. 2a) . Glycositecontaining peptides from each unlabeled cell population ± tunicamycin were mixed with an equivalent amount of heavy labeled glycositecontaining peptides isolated from heavy SILAC-labeled cells, and each glycosite-containing peptide mixture was fractionated into 12 fractions by basic reversed-phase liquid chromatography (bRPLC) before LC-MS/MS analysis of each fraction. From these two samples, we identified 2,044 unique glycosite-containing peptides with an N-X-S/T motif at their N termini at a 1% false-discovery rate (FDR) (Fig. 2b and Supplementary Table 4) .
We previously reported a hydrazide chemistry method for the identification of N-linked glycosites using mass spectrometric analysis of PNGase F released peptides from immobilized glycopeptides by glycans (SPEG) 4, 27 . To determine whether there were differences in the glycosites identified using NGAG from those by the SPEG method, an equivalent amount of cell lysate-derived proteins and the same LC-MS/MS analysis method as used in the NGAG method were also used for glycosite analysis by the SPEG method. This resulted in identification of 1,657 unique N-glycosite-containing peptides (Supplementary Table 5 ). Among these glycosite-containing peptides, 618 overlapped with glycosites identified using the NGAG method. In total, 3,083 unique N-glycosite-containing peptides from 1,473 glycoproteins were identified from OVCAR-3 cells using the SPEG and NGAG methods ( Fig. 2b and Supplementary Table 6 ).
We next used the identified glycans and glycosite-containing peptides to construct a sample-specific database (consisting of all possible combinations of identified glycans and glycosite-containing peptides) for assignment of the tandem MS spectra of intact glycopeptides. The intact glycopeptides were enriched from the tryptic peptides of OVCAR-3 cells using a hydrophilic interaction column (HILIC) and analyzed by LC-MS/MS. The oxonium ioncontaining MS/MS spectra were extracted and assigned to intact glycopeptides in the database using the precursor mass matching option in the GPQuest software 28 . With filtering based on the presence of peptide+HexNAc and/or peptide ions, as well as ≥7 observed b and y ions (1% FDR), we could assign 4,562 oxonium ion-containing spectra to 1,562 unique glycopeptides (containing 518 glycosites and 81 glycans, Supplementary Table 7 ).
The NGAG method was then used to determine quantitative glycoprotein changes in cells treated with tunicamycin. We first determined the precision of glycoprotein quantitation for complex samples using NGAG. Among the glycans and glycosite-containing peptides of OVCAR-3 cells quantified from triplicate NGAG isolations, 97.3% of glycans (Fig. 3a) and 95.4% of glycositecontaining peptides (Supplementary Results and Discussion and Supplementary Figs. 6-9 ) varied less than twofold. Therefore, a twofold change in either direction was used as a reasonable cutoff for The quantification results indicated that 31 out of 64 quantifiable glycans (48.4%) and 359 out of 998 quantifiable glycosite-containing peptides (36%) isolated by the NGAG method decreased more than twofold in the tunicamycin-treated cells (Fig. 3b,c) . These data indicated that the levels of both N-glycans and glycosite-containing peptides decreased in tunicamycin-treated OVCAR-3 cells. To determine whether the decrease of glycosite-containing peptides occurred at the protein expression or glycosylation occupancy levels, we identified and quantified the global proteins from the same treated cells. We identified 87,247 unique peptides from 7,764 protein groups, and the relative abundance of 96.8% (5,953/6,149) of these proteins changed less than twofold after tunicamycin treatment (Fig. 3d) . Using only nonglycosylated peptides for quantification, we found that the relative abundances of the majority of glycoproteins (92.4%, 837/906) were also within a twofold change (Fig. 3e) . However, when we quantified the N-glycosite-containing peptides, we found that 559 of these peptides exhibited greater than twofold decreases (ratio < 0.5) in addition to the changes in total glycoprotein levels ( Fig. 3f) . These data indicate that the decrease of glycosite-containing peptides in tunicamycintreated cells was mainly caused by reduced glycan occupancy (stoichiometry) of the glycosites. This result is consistent with the known inhibitory role of tunicamycin to N-linked glycosylation. The results also showed that the extent of glycosylation alteration could depend on both glycosites and glycans as different glycans and glycosites exhibited different changes (Fig. 3b,c) .
Diverse glycan alterations were observed in tunicamycin-treated OVCAR-3 cells at the total glycan level (Fig. 3b) . To further investigate the pattern of glycan alteration in tunicamycin-treated cells, we focused on the five oligo-mannose glycans (Man5-Man9) for further analysis. Protein glycosylation initiates with the transfer of the glycan precursor Glc 3 Man 9 GlcNAc 2 from dolichol pyrophosphate to Asn-X-Ser/ Thr in newly synthesized glycoproteins 29 . The glycan precursor is trimmed to Man9, then to Man8 and gradually down to Man 5 (ref. 29; Fig. 4a ). Our glycomic results showed that five oligo-mannose glycans were differentially altered with tunicamycin treatment, and the alteration of these five oligo-mannose glycans (Man9-Man5) was apparently associated with the location of the glycan in the N-glycan biosynthesis pathway (Fig. 4b) . The trend in the tunicamycin inhibition was reflected by a readily observable decrease at Man9 (0.26-fold), to a gradual lesser degree of change at Man5 (0.90-fold) npg l e t t e r s (Fig. 4b) . To determine whether this phenomenon could be observed when glycans were attached to a specific glycosite, we performed a site-specific glycosylation analysis using the intact glycopeptide quantification data from the global proteomic data. Our results showed that not all glycosites exhibited this alteration trend. This indicated that alterations of glycosylation occurred in a glycosite-specific manner. Therefore, we reasoned that the observed overall glycan changes might be mainly reflected by the high abundance of glycoproteins. We then selected glycosite Asn217 of Endoplasmin, which had the highest number of spectra at both the glycosite-containing peptide and the intact glycopeptide levels. This glycosite underwent a dramatic decrease at its glycosite-containing peptide level (0.54-fold) with tunicamycin treatment. Five oligo-mannose glycans at the Endoplasmin glycosite Asn217 in tunicamycin-treated OVCAR-3 cells exhibited a similar alteration trend as observed at the total glycan level (Fig. 4c) .
To further investigate the dynamics of the glycosylation changes, OVCAR-3 cells were treated with 1 µM tunicamycin for six different time periods (0, 6, 12, 24, 48 and 72 h). The proteins from the six time points plus repeated 0 and 48 h time points were labeled using 8-plex iTRAQ reagents for quantifying the intact glycopeptides at Endoplasmin glycosite Asn217 at each time point. The results showed that the amount of the Man9 glycan rapidly decreased to 37.2% of its baseline abundance after 6 h of tunicamycin treatment and to 15.7% in 12 h. The abundance of the Man8 glycan slowly decreased to 43.8% in 24 h and to 10.8% after 72 h of tunicamycin treatment, whereas the rate of decrease of the other three oligo-mannose glycans (Man5-Man7) was much slower compared to the Man9's and Man8's (Fig. 4d) . These dynamic alteration results showed that (i) different glycans were altered at different rates, and (ii) that the closer to the reaction that was inhibited by tunicamycin a glycan was located in the N-glycan synthesis pathway, the faster the glycosylation changes occurred.
The observed glycan inhibition pattern by tunicamycin treatment can be explained by the following possible mechanism: the cells usually have some reserves of N-glycan precursor and processing glycoproteins in the endoplasmic reticulum. When the N-glycosylation pathway is inhibited, these reserves can be used to compensate for the effects of the inhibition. However, these reserves may only last for a short time. When the precursor glycans are depleted, the abundance of Man9 begins to decrease. Following the same mechanism, when Man9 is depleted, Man8 starts to decrease, and so on. To a certain degree, the rate of decrease of each oligomannose glycan with tunicamycin treatment could reflect the consumption rates of the glycan in the cells.
Compared to previous work [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , our NGAG method allows the simultaneous large-scale profiling and monitoring of N-linked glycans, glycosites, glycoproteins and site-specific glycosylation in a single method (Supplementary Table 8) . In tunicamycintreated cells, we show that our method detected not only the overall reduction of total glycans and glycosite occupancy, but also the changes in site-specific glycosylation. Such a comprehensive and integrated characterization of protein glycosylation is complementary to genomic, transcriptomic and metabolomic data and is crucial for a complete understanding of the consequences perturbing biological systems.
MeTHods
Methods and any associated references are available in the online version of the paper. 31 . After removing the medium, the cells were washed five times with phosphate buffered saline (PBS, pH 7.4) buffer and then lysed directly with 8 M urea/1 M NH 4 HCO 3 solution 32 . Lysates were briefly sonicated until the solutions were clear. Protein concentrations were determined by BCA protein assay reagent (Thermo Scientific, Fair Lawn, NJ).
Protein digestion. Fetuin, and proteins from normal, tunicamycin-treated and heavy SILAC-labeled OVCAR-3 cells were denatured in 8 M urea/1 M NH 4 HCO 3 buffer, reduced by 10 mM TCEP at 37 °C for 1 h and alkylated by 15 mM iodoacetamide at room temperature in the dark for 30 min. The solutions were diluted fivefold with deionized water. Then sequencing grade trypsin (Promega, Madison, WI; protein: enzyme, 50:1, w/w) was added to the samples and incubated at 37 °C overnight with shaking. Samples were centrifuged at 13,000g for 10 min to remove any particulate matter and purified by a C18 solidphase extraction. Peptides were eluted from the C18 column in 60% ACN/0.1% TFA, and the peptide concentrations were measured by BCA reagent.
Two hundred microgram of peptides from normal and tunicamycin-treated OVCAR-3 cells were mixed with an equivalent amount of heavy SILAC peptides, and the combined samples were further purified by SCX column (Glygen, Columbia, MD) for proteomic analysis.
Extraction of N-linked glycans and glycosite-containing peptides using the NGAG method. One milligram of peptides (400 µl) from fetuin, 3 mg of peptides from normal and tunicamycin-treated OVCAR-3 cells, or 6 mg of peptides from heavy SILAC (K6R10)-labeled OVCAR-3 cells were used for extraction of N-linked glycans and glycosite-containing peptides using the NGAG method. The guanidination of lysine on tryptic peptides was performed according to the Sigma ProteoMass guanidination protocol (Sigma-Aldrich, St. Louis, Missouri) by adding 400 µl of 2.85 M aqueous ammonia and 400 µl of 0.6M O-methylisourea into the peptide solution (final pH = 10.5) and incubating at 65 °C for 30 min (ref. 26) (the volumes and concentrations of the solutions and reagents described here and below were for 1 mg peptides; the volumes and concentrations can be adjusted according to the actual volumes and amounts of the peptides). The reactions were stopped by adding 1.5 ml 10% TFA to adjust the pH to <3. The samples were desalted by C18 column and eluted in 400 µl 60% ACN/0.1% TFA.
The pH of the peptide solution was adjusted to 7.4 by adding 400 µl of 10× PBS buffer (pH 7.4). The peptides were incubated with 1 ml equilibrated AminoLink resin (50% slurry, Pierce, Rockford, IL) in the presence of 50 mM NaCNBH 3 at room temperature for at least 2 h or overnight with shaking. The remaining aldehyde groups on the resin were blocked by 1 M Tris-HCl solution (pH 7.4) in the presence of 50 mM NaCNBH 3 at room temperature for 30 min. The resin was washed three times with water. All carboxyl groups of the peptides, including the sialic acid of glycans, aspartic acid (D) and glutamic acid (E) residues and C termini of peptides, were modified by aniline by incubating beads with 1 M aniline and 0.5 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide(EDC) in 0.2 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer (~pH 5) at room temperature for 6 h or overnight. The EDC solution was added three times (2-4 h intervals) to completely modify the carboxyl groups. The pH of the solution was checked frequently to ensure that it was 4-6 (refs. 33,34).
The resin was washed three times each with 50% ACN and 100 mM NH 4 HCO 3 solution, and resuspended in 100 µl of 100 mM NH 4 The glycosite-containing peptide samples from the normal and tunicamycintreated OVCAR-3 cells were mixed with the same amount of glycositecontaining peptides from the heavy SILAC-labeled cells. The mixtures were dried by vacuum. The glycosite-containing peptides were resuspended in 20 µl 0.2% formic acid (pH < 3) for LC-MS/MS analysis directly or in 50 µl 0.2% FA (pH < 3) for high-performance (HP)LC fractionation.
To determine the reproducibility of the NGAG method, N-linked glycans and glycosite-containing peptides were extracted in triplicate from different amounts of fetuin (100 µg, 100 µg, 200 µg, 300 µg) or the same amount of OVCAR-3 cells (0.5 mg) using NGAG as described above. The glycans (after being purified) and glycosite-containing peptides were directly analyzed by LC-MS/MS.
N-linked glycosite-containing peptide extraction by SPEG method.
N-linked glycosite-containing peptide isolation by the Solid Phase Extraction of Glycopeptide method (SPEG, based on hydrazide chemistry) was performed as described previously 27 with minor modification 36 . Briefly, three milligram of peptides from normal and tunicamycin-treated OVCAR-3 cells were mixed with an equivalent amount of SILAC heavy peptides before SPEG. Glycopeptides in the solution were oxidized by 10 mM NaIO 4 solution at room temperature in the dark for 1 h. The samples were diluted with 0.1% TFA to 5% ACN and cleaned by C18 column, and the elution solution was collected directly into equilibrated hydrazide beads (300 µl of 50% slurry for each sample) and incubated with 100 mM aniline at room temperature for 1 h (ref. 36) . The beads were washed 3 times each with 50% ACN, 1.5 M NaCl, water and 100 mM NH 4 HCO 3 buffer. Former N-glycopeptides were released via 3 µl PNGase F (New England Biolabs, Beverly, MA) in 25 mM NH 4 HCO 3 buffer at 37 °C overnight with shaking. Glycosite-containing peptides were collected in supernatants/wash solutions (200 µl of 50% ACN), and they were dried by vacuum and resuspended in 50 µl 0.2% FA (pH < 3) for HPLC fractionation.
Enrichment of intact glycopeptides using hydrophilic interaction column (HILIC).
The intact glycopeptides were enriched from OVCAR-3 cells using a HILIC enrichment method 37 . Briefly, the tryptic peptides from normal OVCAR-3 cells were purified by C18 and were enriched in 45% ACN/0.1% TFA. The peptide solution (~4 mg peptides) was diluted by 95% ACN/0.1% TFA to a final solvent composition of 80% ACN/0.1% TFA. The HILIC column (SeQuant, Southborough, MA) was washed twice each by 0.1% TFA and 80% ACN/0.1% TFA, followed by sample loading and three washes with 80% ACN/0.1% TFA. The glycopeptides bound to the column were eluted in 0.4 ml of 0.1% TFA solution. The samples were dried by SpeedVac and resuspended in 50 µl of 0.2% FA for high-pH RPLC fractionation. : iTRAQ 118) . The glycosite-containing peptides isolated from different amounts of fetuin were labeled by 4-plex iTRAQ reagents (three sets). The iTRAQ-labeled samples were pooled and purified by SCX and C18 columns for further analysis.
Analysis of glycans using mass spectrometry. N-glycans extracted from bovine fetuin and OVCAR-3 cells using NGAG were analyzed by an Axima MALDI Resonance mass spectrometer (Shimadzu). Dried N-glycans were resuspended in 20 µl deionized water followed by spotting 1 µl glycan sample with 1 µl 2,5-dihydroxybenzoic acid/N,N-dimethylaniline (DHB/ DMA) matrix (100 mg/ml DHB, 2% DMA in 50% acetonitrile, 0.1 mM NaCl) onto a MALDI plate 15, 35 . The laser power was set to 100 for two shots each in 100 locations per spot. The average MS spectra (200 profiles) were used for glycan assignment by GlycoMod software (http://web.expasy. org/glycomod/) and comparison to human glycan database in CFG website (http://www.functionalglycomics.org/) as well as previously analyzed in our laboratory 35, 38 . The possible glycan structures of the identified glycan compositions were generated by GlycoWorkbeach 39 . The identified glycans were further verified by LC-MS/MS (Q-Exactive mass spectrometer, Thermo Fisher Scientific), in which the glycan isotopic mass is more accurate (<10 p.p.m.) than MALDI-TOF-MS, and the glycans with different numbers of sialic acids usually have different retention times on C18 column (due to different number of aniline modifications on the sialic acid). The detailed LC-MS/MS setting is described below. The glycans were directly injected to the analytical C18 column without going through the trap column, and the MS signals were collected from the very beginning of the sample injection in order to detect the underivatived glycans (the neutral glycans that don't have anilinelabeled sialic acids). The glycans identified from the different samples were quantified by a label-free quantification method based on their peak area from LC-MS/MS data using SIEVE software (Thermo Fisher Scientific), and the total ion current (TIC) was used for normalization.
Peptide fractionation using high-pH RPLC. All SILAC light and heavy mixed tryptic peptides (100 µg), iTRAQ-labeled peptides, glycosite-containing peptides (~60 µg), and intact glycopeptides (~40 mg) from OVCAR-3 cells extracted by NGAG and SPEG were injected by a 1220 Series HPLC (Agilent Technologies, Inc., CA) into a Zorbax Extend-C18 analytical column containing 1.8 µm particles at a flow rate of 0. 
LC-MS/MS analysis.
The tryptic peptide and N-linked glycosite-containing peptide samples underwent one LC-MS/MS run per sample (or fraction) on a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Peptides were separated on a Dionex Ultimate 3000 RSLC nano system with a 75 µm × 15 cm Acclaim PepMap100 separating column protected by a 2-cm guard column (Thermo Scientific). The mobile phase flow rate was 300 nl/min and consisted of 0.1% formic acid in water (A) and 0.1% formic acid 95% acetonitrile (B). The gradient profile was set as follows: 4-7% B for 5 min, 7-40% B for 90 min, 40-90% B for 5 min, 90% B for 10 min and equilibrated in 4% B for 10 min. MS analysis was performed using a Q-Exactive mass spectrometer. The spray voltage was set at 2.2 kV. Orbitrap MS1 spectra (AGC 1 × 10 6 ) were collected from 400-1,800 m/z at a resolution of 60 K followed by datadependent higher-energy collisional dissociation tandem mass spectrometry (HCD MS/MS) (resolution 7,500, collision energy 45%, activation time 0.1 ms) of the 20 most abundant ions using an isolation width of 2.0 Da. Charge state screening was enabled to reject unassigned and singly charged ions. A dynamic exclusion time of 25s was used to discriminate against previously selected ions. For tryptic peptides, 100 m/z was set as the fixed first mass in MS/MS fragmentation to include all oxonium ions of glycopeptides.
Database search. All LC-MS/MS data from human and bovine resources were searched against RefSeq human protein databases 40 (downloaded from NCBI website July 29, 2013) and bovine fetuin sequence by MaxQuant 41 (v1.3.0.5), respectively. For global proteome data (tryptic peptide), the search parameters were set as follows: up to two missed cleavage were allowed for trypsin digestion, 20 p.p.m. and 6 p.p.m. precursor mass tolerance for first and main search, respectively; carbamidomethylation (C) was set as a static modification and oxidation (M) was set as a dynamic modification; two modifications with "Arg 10" and "Lys6" were selected as heavy labels for mixed peptides from OVCAR-3 cells; five modifications per peptide and a minimum of six amino-acid length were considered for peptide identification. All other settings were set as default values and the results were filtered with a 1% FDR. For SPEG glycosite-containing peptides data, deamination (N) was added as one additional dynamic modification.
To search LC-MS/MS data of glycosite-containing peptides extracted by NGAG, both human and bovine fetuin databases were first modified by replacing all potential N-glycosylation sites (N # -X-S/T motif, X is any amino acid except proline) with "U" (not existing in normal protein sequences) to facilitate the search parameter setting and N-linked glycosite-containing peptide identification. Then an enzyme "trypsin + U" was created and added to the enzyme list, which was assigned to specifically cleave peptide bonds at the C-terminal side of lysine/arginine (no cleavage at KP and RP) and at the N-terminal side of "U" (168.9642Da). The MaxQuant search parameters were set as follows: up to two missed cleavages were allowed for "trypsin+U" digestion, 20 p.p.m. and 6 p.p.m. precursor mass tolerance for first and main search, respectively; carbamidomethylation (C, +57.0215 Da) was set as a static modification; U->D (U, −53.9373Da), U->N (U that is not at the N termini, −54.9213 Da), guanidination (K, +42.0218 Da), aniline label (D and E that are not at the N termini, protein C termini and K and R that are at any C termini, +75.0473 Da), two aniline labels (D and E that are at the protein C termini, +150.0946 Da), guanidination + aniline label (K at any C termini, +117.0691 Da) and oxidation (M, +15.9949 Da) were set as dynamic modifications; six modifications per peptide and a minimum of six amino-acid length were considered for peptide identification. All other settings were set as default values, and the results were filtered with a 1% FDR. For glycosite-containing peptide data from the OVCAR-3 cell line, which included SILAC peptides, K6+guanidination label (K, +48.0419 Da), K6+guanidination+aniline label (K at any C termini, +123.0892 Da) and R10+aniline label (R at any C termini, +85.0555 Da) were added as additional dynamic modifications based on the parameters used for the global proteome data described above. Two modifications with "Arg 10" and "Lys6" were selected as heavy labels.
Intact glycopeptide analysis. In order to allow Q-Exactive mass spectrometer to select intact glycopeptide peaks for MS/MS analysis, we set "peptide match" as "off ". We also excluded the precursor at charge +1 and +2 for MS/MS, because the intact glycopeptides usually have masses large enough to present as multiple charge states. In order to detect oxonium ions of glycopeptides, we set 100 m/z as the fixed first mass in MS/MS fragmentation, and optimized the MS/MS fragmentation energy to generate the MS/MS spectra of glycopeptides that contained peptide/peptide+HexNAc fragment ions. These fragment ions facilitate the selection of tandem spectra from intact glycopeptides.
The precursor mass matching approach in the GPQuest software was developed for this study and used to identify intact glycopeptides 28 . Briefly, the proteomic raw data were converted to 'mzXML' format using Trans-Proteomic Pipeline (TPP) 42 , and then to 'matlab' format using GPQuest 28 . The oxonium ion-containing MS/MS spectra were extracted using oxonium ion HexNAc_ 204. Note that the oxonium ions were only matched from the top five fragment ions of the MS/MS spectra, as the oxonium ions usually have the highest intensities among fragment ions of N-glycopeptides in HCD fragmentation mode. The oxonium ion-containing spectra were matched to the N-glycopeptide candidate database (comprising the identified N-glycan and glycosite-containing peptides) to assign all glycopeptide candidates of the spectra based on their npg precursor masses within a 10 p.p.m. mass error. The existence of a minimum of two peptide or peptide+HexNAc ions (charge 1+ and 2+, 50 p.p.m. mass error) in MS/MS spectra was used as a filter to determine the glycosite-containing peptide and glycan compositions of the glycopeptides. The quantification information of assigned glycopeptide spectra (based on their MS/MS scan numbers) were obtained from "allpeptide.txt" files from MaxQuant results (SILAC-labeled samples). The b and y ion information from peptide portion of the matched glycopeptides were used for validation.
For iTRAQ-labeled samples, the oxonium ions were matched from the top 20 fragment ions of the MS/MS spectra. The oxonium ion-containing spectra were matched to the N-glycopeptide candidate database (comprising the identified N-glycan and glycosite-containing peptides) to assign all glycopeptide candidates of the spectra based on their precursor masses within a 10 p.p.m. mass error. Then only glycopeptides that contained >30% of the theoretical b and y ions of the peptide portion were included in the final list of identified intact glycopeptides. The quantification information of assigned glycopeptide spectra (based on their MS/MS scan numbers) were obtained from the intensities of the iTRAQ reporter ions.
FDR estimation of intact glycopeptide identification. The false-discovery rate (FDR) of the assignments of spectra to intact glycopeptides of fetuin was estimated using a glycopeptide database established from human immunodeficiency virus (HIV) GP120 glycopeptides that contains 116 N-linked glycans and 17 glycosite-containing peptides (116 × 17 = 1,972 glycopeptide candidates) 23 . Using the same strategy and filters as fetuin glycopeptide identification, only one oxonium ion-containing MS/MS spectrum from triplicate global proteomic analyses was randomly matched to a HIV glycopeptide, which indicated an estimated FDR of 0.1%.
To estimate the FDR of glycopeptide assignment, the decoy peptide database was built by combining the amino acids from all identified glycositecontaining peptides, shuffling them, and separating them into decoy peptide sequences with the same length as the target database. The decoy database was then merged with the target database resulting in a total of 6,166 peptides in the peptide database. The glycopeptide candidate database was then created based on identified glycans with identified and decoy peptides. Using the same match strategy and filters, the oxonium ion-containing spectra were matched to the glycopeptide candidate database and further filtered by the number of matched b and y ions. The FDR of spectrum assignment was estimated using the percentage of spectra that matched to the decoy glycopeptides.
